Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

PIK3CA mutations in vascular malformations.

Castillo SD, Baselga E, Graupera M.

Curr Opin Hematol. 2019 May;26(3):170-178. doi: 10.1097/MOH.0000000000000496.

PMID:
30855339
2.

Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility.

Angulo-Urarte A, Casado P, Castillo SD, Kobialka P, Kotini MP, Figueiredo AM, Castel P, Rajeeve V, Milà-Guasch M, Millan J, Wiesner C, Serra H, Muixi L, Casanovas O, Viñals F, Affolter M, Gerhardt H, Huveneers S, Belting HG, Cutillas PR, Graupera M.

Nat Commun. 2018 Nov 16;9(1):4826. doi: 10.1038/s41467-018-07172-3.

3.

Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling.

Berenjeno IM, Piñeiro R, Castillo SD, Pearce W, McGranahan N, Dewhurst SM, Meniel V, Birkbak NJ, Lau E, Sansregret L, Morelli D, Kanu N, Srinivas S, Graupera M, Parker VER, Montgomery KG, Moniz LS, Scudamore CL, Phillips WA, Semple RK, Clarke A, Swanton C, Vanhaesebroeck B.

Nat Commun. 2017 Nov 24;8(1):1773. doi: 10.1038/s41467-017-02002-4.

4.

Phosphoinositide 3-kinase: a new kid on the block in vascular anomalies.

Castillo SD, Vanhaesebroeck B, Sebire NJ.

J Pathol. 2016 Dec;240(4):387-396. doi: 10.1002/path.4802. Epub 2016 Oct 20. Review.

PMID:
27577520
5.

Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.

Castillo SD, Tzouanacou E, Zaw-Thin M, Berenjeno IM, Parker VE, Chivite I, Milà-Guasch M, Pearce W, Solomon I, Angulo-Urarte A, Figueiredo AM, Dewhurst RE, Knox RG, Clark GR, Scudamore CL, Badar A, Kalber TL, Foster J, Stuckey DJ, David AL, Phillips WA, Lythgoe MF, Wilson V, Semple RK, Sebire NJ, Kinsler VA, Graupera M, Vanhaesebroeck B.

Sci Transl Med. 2016 Mar 30;8(332):332ra43. doi: 10.1126/scitranslmed.aad9982.

6.

Pilot of the brief behavioral activation treatment for depression in latinos with limited english proficiency: preliminary evaluation of efficacy and acceptability.

Collado A, Castillo SD, Maero F, Lejuez CW, Macpherson L.

Behav Ther. 2014 Jan;45(1):102-15. doi: 10.1016/j.beth.2013.10.001. Epub 2013 Oct 16.

7.

Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.

Pros E, Lantuejoul S, Sanchez-Verde L, Castillo SD, Bonastre E, Suarez-Gauthier A, Conde E, Cigudosa JC, Lopez-Rios F, Torres-Lanzas J, Castellví J, Ramon y Cajal S, Brambilla E, Sanchez-Cespedes M.

Int J Cancer. 2013 Aug 15;133(4):898-907. doi: 10.1002/ijc.28090. Epub 2013 Mar 9.

8.

The SOX family of genes in cancer development: biological relevance and opportunities for therapy.

Castillo SD, Sanchez-Cespedes M.

Expert Opin Ther Targets. 2012 Sep;16(9):903-19. doi: 10.1517/14728222.2012.709239. Epub 2012 Jul 26. Review.

PMID:
22834733
9.

Novel transcriptional targets of the SRY-HMG box transcription factor SOX4 link its expression to the development of small cell lung cancer.

Castillo SD, Matheu A, Mariani N, Carretero J, Lopez-Rios F, Lovell-Badge R, Sanchez-Cespedes M.

Cancer Res. 2012 Jan 1;72(1):176-86. doi: 10.1158/0008-5472.CAN-11-3506. Epub 2011 Nov 14.

10.

Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer.

Castillo SD, Angulo B, Suarez-Gauthier A, Melchor L, Medina PP, Sanchez-Verde L, Torres-Lanzas J, Pita G, Benitez J, Sanchez-Cespedes M.

J Pathol. 2010 Sep;222(1):89-98. doi: 10.1002/path.2732.

PMID:
20556744
11.

The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer.

Medina PP, Castillo SD, Blanco S, Sanz-Garcia M, Largo C, Alvarez S, Yokota J, Gonzalez-Neira A, Benitez J, Clevers HC, Cigudosa JC, Lazo PA, Sanchez-Cespedes M.

Hum Mol Genet. 2009 Apr 1;18(7):1343-52. doi: 10.1093/hmg/ddp034. Epub 2009 Jan 19.

PMID:
19153074

Supplemental Content

Loading ...
Support Center